Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
113M
-
Number of holders
-
130
-
Total 13F shares, excl. options
-
116M
-
Shares change
-
+5.19M
-
Total reported value, excl. options
-
$2.11B
-
Value change
-
+$92.2M
-
Put/Call ratio
-
3.88
-
Number of buys
-
82
-
Number of sells
-
-50
-
Price
-
$18.11
Significant Holders of NewAmsterdam Pharma Co N.V. - Common Stock (NAMS) as of Q2 2025
161 filings reported holding NAMS - NewAmsterdam Pharma Co N.V. - Common Stock as of Q2 2025.
NewAmsterdam Pharma Co N.V. - Common Stock (NAMS) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 116M shares
.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (16.6M shares), Bain Capital Life Sciences Investors, LLC (10.7M shares), FCPM III SERVICES B.V. (10.6M shares), RA CAPITAL MANAGEMENT, L.P. (10.1M shares), Capital World Investors (8.39M shares), VIKING GLOBAL INVESTORS LP (6.98M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (5.12M shares), WELLINGTON MANAGEMENT GROUP LLP (3.32M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.01M shares), and JENNISON ASSOCIATES LLC (2.95M shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.